- Home
- XOMA vs AGEN Comparison
XOMA vs AGEN Comparison
Compare XOMA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- AGEN
- Stock Information
- Founded
- XOMA 1981
- AGEN 1994
- Country
- XOMA United States
- AGEN United States
- Employees
- XOMA N/A
- AGEN N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XOMA Health Care
- AGEN Health Care
- Exchange
- XOMA Nasdaq
- AGEN Nasdaq
- Market Cap
- XOMA 320.8M
- AGEN 97.7M
- IPO Year
- XOMA N/A
- AGEN 2000
- Fundamental
- Price
- XOMA $28.59
- AGEN $4.49
- Analyst Decision
- XOMA Strong Buy
- AGEN Buy
- Analyst Count
- XOMA 2
- AGEN 3
- Target Price
- XOMA $78.50
- AGEN $10.00
- AVG Volume (30 Days)
- XOMA 18.9K
- AGEN 339.2K
- Earning Date
- XOMA 11-05-2024
- AGEN 11-05-2024
- Dividend Yield
- XOMA N/A
- AGEN N/A
- EPS Growth
- XOMA N/A
- AGEN N/A
- EPS
- XOMA N/A
- AGEN N/A
- Revenue
- XOMA $15,239,000.00
- AGEN $159,630,000.00
- Revenue This Year
- XOMA $456.45
- AGEN N/A
- Revenue Next Year
- XOMA $29.84
- AGEN $0.04
- P/E Ratio
- XOMA N/A
- AGEN N/A
- Revenue Growth
- XOMA 277.95
- AGEN 60.67
- 52 Week Low
- XOMA $14.27
- AGEN $4.18
- 52 Week High
- XOMA $30.50
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- XOMA 53.55
- AGEN 40.14
- Support Level
- XOMA $28.66
- AGEN $4.50
- Resistance Level
- XOMA $30.50
- AGEN $4.78
- Average True Range (ATR)
- XOMA 1.07
- AGEN 0.28
- MACD
- XOMA 0.21
- AGEN 0.02
- Stochastic Oscillator
- XOMA 55.56
- AGEN 42.47
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).